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After Bone Marrow Xenotransplantation in· the~ Reciprocal Hamster 
to Rat Animal Models 
F. Pan, M. Tsugita, A.S. Rao, Y. Wakizaka, H. Sun, I.Y. Park, J.J. Fung, T.E. Starzl, and L.A. Valdivia 
BONE marrow transplantation (BMTx) following lethal irradiation is an established modality to induce donor-
specific tolerance in the rat to mouse xenogeneic combina-
tion. 1 The induction of donor-specific tolerance in this 
model is accompanied by a distinct absence of graft-versus-
host disease (GVHD). The latter outcome, however, is not 
witnessed when BMTx is performed in hamster to rat strain 
combinations in which, despite splenectomy (Spx), the 
recipients invariably succumb to lethal GVHO.2 The advent 
of tacrolimus (TCL. FK 506) as a potent immunosuppres-
sive agent for the prevention and treatment of GVHO in 
allogeneic BMT~.4 prompted us to assess its efficacy on 
engraftment and GVHO after BMTx in the reciprocal 
hamster to rat xenograft combination. 
MATERIALS AND METHODS 
Animals. Syrian hamsters (100 to 120 g) and LEW rats (180 to 
220 g) were used as donors and recipients. respectively. 
Bone Marrow Transplantation. LEW recipients were splenecto-
mized 7 days before BMTx and injected with 3 x IO~ unfraction-
ated hamster bone marrow cells (BMC) following irradiation (10.5 
Gy). The hamster recipients received a similar quantity of LEW 
BMC and irradiation dose but were not subjected to Spx. Failure of 
BM to engraft was defined as recipient death within 14 days 
postinfusion without recovery of peripheral white blood cell count. 
Experimental groups are depicted in Table l. 
Tacrolimus. FK 506 (1 mgikg/d: 1M) was given daily to the 
recipients from days 0 to 30. 
DetectIOn of Chimensm. The presence of donor cells in the 
recipient's peripheral hlood was determined hy flow (.-ytometry 
\Ising LEW antihamster or hamster anti-LEW IgG antihodies. 
\\hich were prepared hy immunization of the appropriate animals 
with splenocytes. The IgG fraction was obtained by purification 
using gel chromatography. The primary antibody was biotinylated 
and PE-labeled streptavidin was used for its identification. 
GVHD. Oinica1 cutaneous and/or hepatic manifestations of 
GVHD were confirmed by histopathological examination and 
immunostaining. 
RESULTS AND DISCUSSION 
Failure of engraftment (FE) was witnessed in all rats 
preconditioned with irradiation followed by hamster BMTx 
(Table 1, group II) with the addition of TCL having no 
beneficial effect (group III). Interestingly the use of a 
similar regimen in the reciprocal rat to hamster strain 
combination resulted in much lower FE and markedly 
prolonged animal survival with no evidence of GVHO at 
day 30 (group VIII). Splenectomy prior to irradiation and 
BMTx in the hamster to rat model also resulted in a much 
lower FE but with obvious manifestations of cutaneous 
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Table 1. Failure of Engraftment (FE), GVHD. and Survival of Recipients After BMTx in the ReCiprocal Hamster 
to Rat Xenograft Combination 
Group Treatment n FE(%) 
A. Hamster to rat I Radiation (Rad)' alone 5 100 
II Rad + BMTx* 6 100 
III Rad + BMTx ~ TCl§ 7 100 
IV Rad + BMTx + Spx 22 100 
V Rad + BMTx T Spx + TCl 10 0 
B. Rat to hamster 
N/A ~ not applicable . 
. Postoperative day. 
"0.5 Gy. 
VI Rad alone 
VII Rad ... BMTx 
VIII Rad + BMTx ,. TCl 
'3 '. '0' untracllOnated BM cells. 
';, mg/kgld 1M: 0-30 days. 
5 100 
39 49 
10 20 
GVHD(%) 
Survival (days) 
(at POD' 30\ Max Median Min 
N/A 9 8 6 
N/A 20 13 11 
N/A 15 10 5 
27 59 21 14 
0 44 40 34 
N/A 8 8 6 
28 112 20 7 
0 131 91 9 
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EFFECT OF TACROLIMUS AND SPLENECTOMY 
GVHD (group IV). However, the administration of TCL to 
group IV animals resulted in complete abrogation of FE 
and of cutaneous GVHD, which markedly prolonged their 
survival. The animals in groups IV and V nevertheless 
succumbed to lethal GVHD, which was essentially limited 
to the liver. 
In splenectomized TeL-treated rats, which enjoyed mod-
erately prolonged survival (group V) following hamster 
BMTx, 80% of peripheral blood cells at 14 days postinfu-
sion were of hamster origin. Interestingly, reconstitution 
with hamster RBCs was only possible in animals in group V. 
When tested in CDC assays, hamster serum (unlike that 
from naive LEW rats) had no detectable titers of antirat 
preformed antibodies, which may provide an explanation 
for the relative ease with which engraftment could be 
achieved in the rat to hamster strain combination. Taken 
together, these data support earlier observations that nat-
737 
ural (preformed) antibodies are the main barrier to xeno-
geneic bone marrow engraftment.5 Furthermore, Spx prior 
to BMTx across xenogeneic barriers enhances engraftment, 
an effect further supplemented by TCL, which also attenu-
ates cutaneous (but not hepatic) manifestations of GVHD. 
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